Skip to main content
. 2014 Oct 2;33(1):83. doi: 10.1186/s13046-014-0083-8

Figure 5.

Figure 5

Disease-free survival in patients under adjuvant 5-FU/FA versus 5-FU/FA/irinotecan in relation to VEGF-D expression. A. Disease-free survival rates in the total population, B. Patients under adjuvant 5-FU/FA, C. Patients under adjuvant 5-FU/FA/irinotecan.